ERBB2 and neoplasm: By leveraging receptor-mediated endocytosis, T-DM1 (Fig. 1) selectively delivers the cytotoxic drug DM1 to HER-2-positive cells, sparing non-transformed cells and HER-2-negative tumor cell lines from cytotoxic effects [11].